HIV感染者黄热病疫苗长期免疫应答取决于HIV RNA抑制状态
该研究纳入247名瑞士HIV队列中确诊HIV后首次接种黄热病疫苗者,用PRNT检测接种后1、5、10年免疫应答。接种时83%患者HIV RNA<400 copies/mL,PRNT反应性比例1年内95%、5年86%、10年75%;HIV RNA抑制者各时点均高。结论:长期应答主要取决于接种时HIV复制控制,成功cART者10年应答与非HIV成人相当。
要点
- HIV感染者接种黄热病疫苗后10年免疫应答主要取决于接种时HIV RNA是否抑制。
- 接种时HIV RNA抑制者PRNT反应性1年99%、5年99%、10年100%。
- 成功cART者建议10年后单剂加强,HIV RNA未控制者可能需早期加强。
核心结论
- HIV感染者接种黄热病疫苗后长达10年的免疫应答主要取决于接种时HIV复制的控制情况。
- 成功cART者10年免疫应答与非HIV感染成人相当。
研究设计与样本
- 研究纳入瑞士HIV队列研究(SHCS)中247名确诊HIV后首次接种黄热病疫苗的参与者。
- 用黄热病斑块减少中和试验(PRNT)检测储存血样接种后1年、5年、10年的免疫应答。
- PRNT≥1:10视为反应性且具有保护性,用Poisson回归分析接种反应预测因素。
主要发现
- 接种时82%的接种者正在接受联合抗逆转录病毒治疗(cART),83% HIV RNA抑制(<400 copies/mL),中位CD4 T细胞计数536 cells/μL。
- 总体PRNT反应性比例:接种前46%(95%CI 38%-53%),1年内95%(95%CI 91%-98%),5年86%(95%CI 79%-92%),10年75%(95%CI 62%-85%)。
- 接种时血浆HIV RNA抑制者PRNT反应性比例:1年内99%(95%CI 95%-99.8%),5年99%(95%CI 92%-100%),10年100%(95%CI 86%-100%)。
关键数值与推荐
- PRNT≥1:10视为反应性且具有保护性。
- 成功cART者建议10年后单剂黄热病疫苗加强。
- 接种时HIV RNA未控制者可能需要早期加强。
临床怎么用
- 对HIV感染者接种黄热病疫苗前应评估HIV RNA抑制状态。
- 成功cART且HIV RNA抑制者可按10年后单剂加强策略管理。
- HIV RNA未控制者接种后可能需要更早加强,应加强免疫监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In human immunodeficiency virus (HIV)-infected individuals, the immune response over time to yellow fever vaccination (YFV) and the necessity for booster vaccination are not well understood. METHODS: We studied 247 participants of the Swiss HIV Cohort Study (SHCS) with a first YFV after HIV diagnosis and determined their immune responses at 1 year, 5 years, and 10 years postvaccination by yellow fever plaque reduction neutralization titers (PRNTs) in stored blood samples. A PRNT of 1:≥10 was regarded as reactive and protective. Predictors of vaccination response were analyzed with Poisson regression. RESULTS: At vaccination, 82% of the vaccinees were taking combination antiretroviral therapy (cART), 83% had suppressed HIV RNA levels (<400 copies/mL), and their median CD4 T-cell count was 536 cells/μL. PRNT was reactive in 46% (95% confidence interval [CI], 38%-53%) before, 95% (95% CI, 91%-98%) within 1 year, 86% (95% CI, 79%-92%) at 5 years, and 75% (95% CI, 62%-85%) at 10 years postvaccination. In those with suppressed plasma HIV RNA at YFV, the proportion with reactive PRNTs remained high: 99% (95% CI, 95%-99.8%) within 1 year, 99% (95% CI, 92%-100%) at 5 years, and 100% (95% CI, 86%-100%) at 10 years. CONCLUSIONS: HIV-infected patients' long-term immune response up to 10 years to YFV is primarily dependent on the control of HIV replication at the time of vaccination. For those on successful cART, immune response up to 10 years is comparable to that of non-HIV-infected adults. We recommend a single YFV booster after 10 years for patients vaccinated on successful cART, whereas those vaccinated with uncontrolled HIV RNA may need an early booster.
引用
- Veit O, Domingo C, Niedrig M, et al. Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. Clin Infect Dis. 2018. PMID: 29140432. doi:10.1093/cid/cix960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。